Form 4 for RXRX RECURSION PHARMACEUTICALS, INC.
Accepted 2026-09-10 17:55:57 ET · period of report 2026-09-08 · accession 0001601830-26-000105 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| T | 2026-09-10 17:55 | 2026-09-08 | RXRX | Khan Najat | CEO, Pres, Dir | S - Sale | $3.52 | -22.4K | 2.07M | -1% | -$78.8K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Class A Common Stock | 2026-09-08 | S | D | 22,408 | $3.52 | 2,072,890 | D | — | — | (F1) This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 22, 2025. (F2) This transaction was executed in multiple trades at prices ranging from $3.485 to $3.58. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. |